New advances in drug discovery.
The conference covered the most exciting recent advances in industry and academia in areas related to drug discovery and development. Topics included candidates currently in clinical development, new technologies aimed at facilitating the drug discovery process and potential new targets. Targets in clinical development included inhibitors of lipoprotein-associated phospholipase A2 for atherosclerosis, IL-1beta converting enzyme inhibitors for inflammatory disorders and a novel proteasome inhibitor for cancer therapy. New technologies covered a novel system for screening ion channel function, various applications for RNA interference, different imaging modalities, as well as mRNA microarrays to facilitate toxicological assessment. New targets included the ATP-binding cassette family of transporters and the recently elucidated sulfation pathways.
GlaxoSmithKline, Department of Vascular Biology and Thrombosis, King of Prussia, PA, USA. Colin.H.Macphee@gsk.com
Colin
C
Macphee
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends*; D015195:Drug Design; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D051381:Rats